Domov › Rak krvi › New York › New York City
Klinične študije za Rak krvi v New York City, NY
26 študij za Rak krvi išče udeležence na lokacijah v New York City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Vključevanje udeležencevFaza 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Vključevanje udeležencevFaza 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Vključevanje udeležencevFaza 1
- NYU Langone Health, New York
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 2
- Mount Sinai Medical Center, New York
Genomic Profiling in Cancer Patients
Vključevanje udeležencevOpazovalna študija
- Metropolitan Hospital Center, New York
- Ralph Lauren Center for Cancer Care and Prevention, New York
- Memorial Sloan Kettering Cancer Center, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Vključevanje udeležencevFaza 3
- David H. Koch Center for Cancer Care, New York
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Vključevanje udeležencevFaza 1/2
- Research Site, New York
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Vključevanje udeležencevFaza 3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
- Weill Cornell Medical Center, New York
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College-NY Presbyterian Hospital, New York
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
Vključevanje udeležencevVabljeni zdravi prostovoljci
- NYP/Weill Cornell Medical Center, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Vključevanje udeležencevFaza 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Vključevanje udeležencevOpazovalna študija
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital at Cornell, New York
- Mount Sinai Medical Center - New York, New York
- in še 3
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Vključevanje udeležencevFaza 2
- New York University (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
IVIG for Infection Prevention After CAR-T-Cell Therapy
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center, New York
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Vključevanje udeležencevFaza 3
- New York Presbyterian Hospital, New York
- Mt Sinai Medical Center, New York
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Vključevanje udeležencevOpazovalna študija
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Vključevanje udeležencevVabljeni zdravi prostovoljci
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Vključevanje udeležencevFaza 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Vključevanje udeležencevFaza 1
- New York - Presbyterian / Weill Cornell Medicine, New York
- Mount Sinai - Ruttenberg Treatment Center, New York
- Columbia University Medical Center, New York
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Vključevanje udeležencevOpazovalna študija
- Memorial Sloan Kettering Cancer Center, New York
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Vključevanje udeležencevFaza 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
Študije za Rak krvi v drugih mestih
- Houston, TX46 študij
- Boston, MA25 študij
- Washington, DC19 študij
- Seattle, WA18 študij
- Baltimore, MD18 študij
- Los Angeles, CA17 študij
- Durham, NC16 študij
- Chicago, IL15 študij
- Philadelphia, PA14 študij
- Columbus, OH13 študij
- Edison, NJ13 študij
- Nashville, TN13 študij
Druge študije v New York City
- Rak dojke136 študij
- Nemalicelični pljučni rak121 študij
- Rak (vse vrste)109 študij
- Rak prostate103 študij
- Metastatski rak93 študij
- Kolorektalni rak78 študij
- Rak jajčnikov69 študij
- Rak pljuč60 študij
- Množni mielom60 študij
- Rak trebušne slinavke60 študij
- Rak endometrija52 študij
- Akutna mieločna levkemija51 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.